[Deep vein thrombosis: new drugs and future therapeutic perspectives].
Prevention and treatment of the venous thromboembolic phenomena should be modified in a near future. The arrival of two new classes of anticoagulants: antifactor Xa and anti-factor IIa, opens a new perspective in an area in which low molecular weight heparins and oral anticoagulants have the exclusivity. Fondaparinux has the approval for its introduction into the market as a maximum representative of this group and has begun to be used. Among the direct antithrombotics we find melagatran and its oral form, ximelagatran, that opts to be the substitute of oral anticoagulants.
García Vidal
R
R
Angiología y Cirugía Vascular, Hospital Universitario Joan XXIII, Tarragona, España. ragavid@yahoo.es
Berga Fauria
C
C
Paredero
V M
VM
D000990:Antithrombin III / Q000627:therapeutic use*; D000991:Antithrombins / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use*; D001596:Benzylamines / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D000077425:Fondaparinux; D005544:Forecasting; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000188:drug therapy*
D000991:Antithrombins; D001384:Azetidines; D001596:Benzylamines; D005343:Fibrinolytic Agents; D011134:Polysaccharides; C426686:ximelagatran; D000990:Antithrombin III; D000077425:Fondaparinux